Drug intelligence / Profile preview

PRX103

Development stage: Preclinical
Lead developer: Prazer Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

PRX103 is a proteolysis-targeting chimera (PROTAC) drug candidate that functions as a BRD4 inhibitor. It is being developed by Praser Therapeutics for the treatment of hematologic neoplasms and other cancers. The drug's mechanism involves targeting bromodomain-containing protein 4 (BRD4), which plays a key role in regulating gene expression involved in cancer cell proliferation and survival. As of May 2025, its highest development status is preclinical.

Targets

BRD4 (Bromodomain-containing protein 4)

Beyond the preview

Go deeper on PRX103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRX103.

Explore the full profile